Skip to main content
. 2016 Dec 4;8(10):17347–17359. doi: 10.18632/oncotarget.14468

Figure 6.

Figure 6

Comparisons of FLT-1 expressions in each group by IHC (× 400) (A, FLT-1 expressions in the Vector group; B, FLT-1 expressions in the Vector group in the pcDNA-ANRIL group; C, FLT-1 expressions in the shANRIL group; D, FLT-1 expressions in the PDTC group; E, FLT-1 expressions in the pcDNA-ANRIL + PDTC group. Compared with the Vector group, expression of FLT-1 was increased in the pcDNA-ANRIL group, while expression of FLT-1 was decreased in the shANRIL group and the PDTC group. Compared with the pcDNA-ANRIL group, expression of FLT-1 was evaluated in the pcDNA-ANRIL + PDTC group). Notes: IHC, immunochemistry; FLT-1, FMS-like tyrosine kinase-1; VEGF, vascular endothelial growth factor; The Vector group, injected with 800 ng/kg empty plasmid; The shANRIL group, injected with 800 ng/kg lncRNA ANRIL knockout plasmid; The PDTC group, injected with 800 ng/kg NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC); The pcDNA-ANRIL + PDTC group, injected with PDTC after lncRNA ANRIL overexpression; DM, diabetes mellitus; CI, cerebral infarction.